Latest Factor VIII Stories

BEIJING, Nov. 13 /PRNewswire/ -- Bayer Schering Pharmaceuticals, the leading pharmaceutical company in China and a global leader in hemophilia care, announced today a euro 1.5 million pledge to develop Hemophilia Treatment Centers (HTCs) throughout China. Over the next five years, Bayer's support will fund a variety of necessities, including equipment and supplies, patient programs, educational materials, medical training and nursing support. The Bayer China Hemophilia Treatment Center...

NEW YORK, Nov. 12 /PRNewswire/ -- Val Bias, Chief Executive Officer of the National Hemophilia Foundation is featured in the November 2008 issue of Black Enterprise magazine in the "On the Move" section of the Powerplay Department. The department highlights African-American men and women who have been appointed to new management positions in the upper echelons of the corporate world. Recent announcements have included leadership posts at BET, MTV and Northrop Grumman. Black Enterprise...

STOCKHOLM, Sweden and MADISON, New Jersey, USA - November 12, 2008. Biovitrum AB (publ) (STO: BVT) and Wyeth (NYSE: WYE) today announced an extension of the ReFacto(R) supply agreement until December 31, 2015. Biovitrum will continue to be the sole producer of drug substance for Wyeth for ReFacto(R), as well as Xyntha(R)/ReFacto(R) AF, the successor products, and will continue to receive royalties from Wyeth's global sales. Biovitrum's co-promotion rights in the Nordic region...

The European Medicines Agency (EMEA) has granted license approval to Bayer HealthCare LLC (Bayer) for its new sterile filling facility (SFF) on its Berkeley, Calif. campus. The approval closely follows authorization already given by the U.S. Food and Drug Administration in August 2008. Together, these licenses from the regulatory bodies ensure this state-of-the-art facility is ready to support the supply of Bayer's Kogenate(R) FS/ KOGENATE(R) Bayer (Antihemophilic Factor (Recombinant)) line...

The U.S. Food and Drug Administration has approved a new use for the blood product Kogenate FS in children with the most severe form of hemophilia. The FDA said Kogenate FS is meant to reduce the frequency of bleeding episodes and prevent joint damage in such children. Hemophilia A is a rare, hereditary, bleeding disorder in which a protein needed to form blood clots, factor VIII, is missing or its level is reduced. The FDA said the disorder affects about 15,000 individuals in the United...

BERKELEY, Calif., Oct. 10 /PRNewswire/ -- Bayer HealthCare LLC announced today that the U.S. Food and Drug Administration (FDA) has approved routine prophylaxis with Kogenate(R) FS Antihemophilic Factor (Recombinant) to reduce the frequency of bleeding episodes and the risk of joint damage in patients aged 0-16 years with severe hemophilia A with no pre-existing joint damage. This important approval provides these patients with the only factor VIII treatment that the FDA has determined safe...

China Biologic Products, a plasma-based pharmaceutical company, has received approval from the People's Republic of China State Food and Drug Administration to commence clinical trial of its new human coagulation Factor VIII product, a coagulation treatment for hemophilia and mass hemorrhaging. As one of four suppliers of cryoprecipitate in China, China Biologic has been engaged in a contract to supply cryoprecipitate to Green Cross China for use in the production of human coagulation factor...

Wyeth Pharmaceuticals, a division of Wyeth, has announced that product shipments have begun for Xyntha antihemophilic factor, plasma/albumin-free, a new recombinant factor VIII product for both the control and prevention of bleeding episodes and surgical prophylaxis in patients with hemophilia A, a rare, inherited blood-clotting disorder. Xyntha is produced using manufacturing and purification processes designed to reduce the risk of viral contamination. The manufacturing process for Xyntha...

COLLEGEVILLE, Pa., Sept. 8 /PRNewswire/ -- Wyeth Pharmaceuticals, a division of Wyeth , announced today that product shipments have begun for XYNTHA(TM) Antihemophilic Factor (Recombinant), Plasma/Albumin-Free, a new recombinant factor VIII product for both the control and prevention of bleeding episodes and surgical prophylaxis in patients with hemophilia A, a rare, inherited blood-clotting disorder. XYNTHA is produced using state-of-the-art manufacturing and purification processes...

KING OF PRUSSIA, Pa., Aug. 25 /PRNewswire/ -- Hemophilia A patients who use Helixate(R) FS, Antihemophilic Factor (Recombinant), and their treatment providers are now tracking treatment progress in real time, thanks to the HeliTraxSM System, a state-of-the-art wireless Internet-based data management system recently introduced by CSL Behring. The system allows for a comprehensive view of a patient's progress, with young patients relaying information about bleeding events and their use of...